Search results for "48"

showing 10 items of 1388 documents

Peritoneal cavity phagocytes from the teleost sea bass express a glucocorticoid receptor (cloned and sequenced) involved in genomic modulation of the…

2005

Abstract To gain further insight into the role of cortisol in Wsh innate immune responses, we cloned and sequenced a 2592 bp cDNA from sea bass (Dicentrarchus labrax) peritoneal leukocytes (PCLs) encoding a glucocorticoid receptor (DlGR1). The deduced aminoacid sequence displayed that DlGR1 belong to a multigenic family of steroid hormone receptors, and exhibited high homology (80%) to the Burton’s mouth breeder (Haplochromis burtoni) HbGR1. The DlGR1 functional domains presented homologies with those of several vertebrate species. In situ hybridization assay revealed that DlGR1 was expressed in macrophages and neutrophils from the peritoneal cavity. Since in a previous paper, sea bass PCL …

medicine.medical_specialtyDNA ComplementaryHydrocortisonemedicine.medical_treatmentMolecular Sequence DataDicentrarchus labrax; Peritoneal cavity leukocytes; Phagocytes; Hydrocortisone; RU486; Glucocorticoid receptor; DlGR1; GR cDNA sequence; GR mRNA expressionSequence HomologyGlucocorticoid receptorBiologyDlGR1Peritoneal cavitychemistry.chemical_compoundEndocrinologyGlucocorticoid receptorReceptors GlucocorticoidInternal medicinemedicineAnimalsDicentrarchus labraxPeritoneal cavity leukocyteAmino Acid SequenceSea bassReceptorPeritoneal CavityCells CulturedRespiratory BurstPhagocytesInnate immune systemDose-Response Relationship DrugZymosanZymosanMolecular biologyRespiratory burstSteroid hormoneGR mRNA expressionmedicine.anatomical_structureEndocrinologychemistryPhagocyteLuminescent MeasurementsGR cDNA sequenceAnimal Science and ZoologyBasshormones hormone substitutes and hormone antagonistsStress PsychologicalRU486
researchProduct

Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency

2019

Background Dual-release hydrocortisone (DR-HC) improves metabolism in patients with adrenal insufficiency. The aims of this study were to compare the cardiovascular and metabolic effects of conventional glucocorticoids (GCs) vs. DR-HC and of high vs. low doses of GCs, after 48 months of observation. Methods We selected 27 patients on hydrocortisone (mean dose 17.5 ± 4.2 mg/day) and 20 patients on cortisone acetate (mean dose 37.5 ± 12.1 mg/day) who maintained this treatment (group A) and 53 patients switched to DR-HC (mean dose 22 ± 4.8 mg/day) (group B). At baseline and after 48 months, clinical and metabolic parameters and Framingham Risk Score (FRS) were obtained. Results After 48 month…

medicine.medical_specialtyDiabetes mellituWaistDual releaseEndocrinology Diabetes and MetabolismUrology030209 endocrinology & metabolismlcsh:Diseases of the endocrine glands. Clinical endocrinologyConventional glucocorticoidGroup BSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusInternal MedicineAdrenal insufficiencymedicineHydrocortisonelcsh:RC648-665Framingham Risk Scorebusiness.industryResearchconventional glucocorticoidsmedicine.diseaseCardiovascular riskBlood pressure030220 oncology & carcinogenesisdiabetes mellitusDual-release hydrocortisonebusinessAdrenal insufficiencymedicine.drug
researchProduct

SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class

2019

Abstract Background For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME. Expert opinion To debate newly available CVOT data and to put them into…

medicine.medical_specialtyDiabetes mellitus type 2 ; drug therapy ; Cardiovascular diseases ; drug therapy ; Canagliflozin ; therapeutic use ; Benzhydryl compounds ; therapeutic use ; Glucosides ; therapeutic use ; Sodium-Glucose Transporter 2 Inhibitors ; therapeutic useEndocrinology Diabetes and MetabolismEmpagliflozin610 Medicine & health030209 endocrinology & metabolismContext (language use)ComorbidityType 2 diabetesDiseaseCanagliflozin ; Cardiovascular disease ; Dapagliflozin ; Empagliflozin ; SGLT2 inhibitor ; Type 2 diabetes.lcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDiabetes mellitusCorrespondenceEmpagliflozinHumansMedicine030212 general & internal medicineCanagliflozinDapagliflozinIntensive care medicineSodium-Glucose Transporter 2 InhibitorsCanagliflozinlcsh:RC648-665business.industryIncidence616.379-008.64 [udc]Type 2 diabetesSGLT2 inhibitorGeneral MedicineDapagliflozinCardiovascular diseasePrognosismedicine.disease3. Good healthEastern europeanDiabetes Mellitus Type 2chemistryCardiovascular Diseasesbusinessmedicine.drug
researchProduct

Diabetes mellitus secondary to Cushing's disease

2018

Associated with important comorbidities that significantly reduce patients’ overall wellbeing and life expectancy, Cushing’s disease (CD) is the most common cause of endogenous hypercortisolism. Glucocorticoid excess can lead to diabetes, and although its prevalence is probably underestimated, up to 50% of patients with CD have varying degrees of altered glucose metabolism. Fasting glycemia may nevertheless be normal in some patients in whom glucocorticoid excess leads primarily to higher postprandial glucose levels. An oral glucose tolerance test should thus be performed in all CD patients to identify glucose metabolism abnormalities. Since diabetes mellitus (DM) is a consequence of cortis…

medicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismDisease030204 cardiovascular system & hematologyCarbohydrate metabolismlcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health sciences0302 clinical medicineInsulin resistanceCortisol-lowering medication; Cushing's disease; Diabetes; Glucocorticoids; Insulin resistance; Endocrinology Diabetes and MetabolismEndocrinologyInternal medicineDiabetes mellitusmedicineGlucocorticoidslcsh:RC648-665business.industryDiabetesInsulin resistanceCushing's diseaseCushing’s diseasemedicine.diseaseDiabetes and MetabolismEndocrinologyPostprandialCortisol-lowering medicationCushing's diseasePituitary surgerybusinessGlucocorticoidmedicine.drug
researchProduct

Diabetes Secondary to Acromegaly: Physiopathology, Clinical Features and Effects of Treatment.

2018

Acromegaly is a rare disease due to chronic GH excess and to the consequent increase in IGF-1 levels. Both GH and IGF-1 play a role in intermediate metabolism affecting glucose homeostasis. Indeed, chronic GH excess impairs insulin sensitivity, increases gluconeogenesis, reduces the glucose uptake in adipose tissue and muscle and alters pancreatic β cells function. As a consequence, glucose metabolism alterations are a very frequent complication in acromegaly patients, further contributing to the increased cardiovascular risk and mortality. Treatment modalities of acromegaly differently impact on glucose tolerance. Successful surgical treatment of acromegaly ameliorates glucose metabolism a…

medicine.medical_specialtyGlucose uptakeMini Reviewglucose metabolismEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismCarbohydrate metabolismpituitary tumorlcsh:Diseases of the endocrine glands. Clinical endocrinologySettore MED/13 - EndocrinologiaImpaired glucose tolerance03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicineDiabetes mellitusAcromegalymedicineGlucose homeostasislcsh:RC648-665diabetesbusiness.industrymedicine.diseasePasireotideGHEndocrinologyimpaired glucose toleranceAcromegaly Diabetes GH Glucose metabolism IGF-1 Impaired glucose tolerance Pituitary tumor Endocrinology Diabetes and Metabolismchemistry030220 oncology & carcinogenesisPegvisomantAcromegalyIGF-1businessmedicine.drug
researchProduct

Effect of the Alterations in Contractility and Morphology Produced by Atrial Fibrillation on the Thrombosis Potential of the Left Atrial Appendage

2021

Atrial fibrillation (AF) is a common arrhythmia mainly affecting the elderly population, which can lead to serious complications such as stroke, ischaemic attack and vascular dementia. These problems are caused by thrombi which mostly originate in the left atrial appendage (LAA), a small muscular sac protruding from left atrium. The abnormal heart rhythm associated with AF results in alterations in the heart muscle contractions and in some reshaping of the cardiac chambers. This study aims to verify if and how these physiological changes can establish hemodynamic conditions in the LAA promoting thrombus formation, by means of computational fluid dynamic (CFD) analyses. In particular, sinus …

medicine.medical_specialtyHistologythromboembolic eventleft atrial appendagelcsh:Biotechnology0206 medical engineeringBiomedical EngineeringThrombogenicityHemodynamicsBioengineering02 engineering and technology030204 cardiovascular system & hematologyContractilitySettore ING-IND/14 - Progettazione Meccanica E Costruzione Di Macchine03 medical and health sciencescomputational fluid dynamic0302 clinical medicinecardiac wall motionInternal medicinelcsh:TP248.13-248.65Medicineatrial fibrillationThrombusStrokeOriginal ResearchFibrillationbusiness.industrySettore ING-IND/34 - Bioingegneria IndustrialeBioengineering and BiotechnologyAtrial fibrillationmedicine.disease020601 biomedical engineeringThrombosisCardiologymedicine.symptombusinessBiotechnologyFrontiers in Bioengineering and Biotechnology
researchProduct

Psychometric assessment using classic neuropsychological and virtual reality based test: A study in obsessive-compulsive disorder (OCD) and schizophr…

2014

Assessment of neurocognitive functioning is a critical task in clinical settings. In many disorders, cognitive impairment precedes the onset of behavioral symptoms, and cognitive decline is a major factor contributing to functional disability. The purpose of the current study was to evaluate the executive functions by comparing the evaluations obtained using a neuropsychological battery with the one obtained using the virtual reality version of the Multiple Errands Test (V-MET). The study population included three groups: 10 patients affected by Obsessive Compulsive Disorder (OCD); 10 Schizophrenic patients; 10 healthy Controls. The results identified executive problems in clinical samples.…

medicine.medical_specialtyObsessive-compulsive disorder; Schizophrenia; Virtual reality Neuropsychological assessmentmedicine.diagnostic_testNeuropsychologySettore M-PSI/03 - PsicometriaVirtual reality Neuropsychological assessmentExecutive functionsmedicine.diseaseTest (assessment)SchizophreniamedicineSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.Obsessive-compulsive disorderSchizophreniaSettore M-PSI/01 - PSICOLOGIA GENERALENeuropsychological assessmentObsessive-compulsive disorder Schizophrenia Virtual reality Neuropsychological assessmentCognitive declinePsychiatryPsychologyObsessive-compulsive disorder (OCD)NeurocognitiveSettore MED/25 - PsichiatriaClinical psychology
researchProduct

Descriptive Epidemiology of Human Thyroid Cancer: Experience From a Regional Registry and The “Volcanic Factor”

2013

Thyroid cancer (TC), the most common endocrine tumor, has steadily increased worldwide due to the increase of the papillary histotype. The reasons for this spread have not been established. In addition to more sensitive thyroid nodule screening, the effect of environmental factors cannot be excluded. Because high incidences of TC were found in volcanic areas (Hawaii and Iceland), a volcanic environment may play a role in the pathogenesis of TC.In January 2002, the Regional Register for Thyroid Cancer was instituted in Sicily. With a population of approximately 5 million inhabitants with similar genetic and lifestyle features, the coexistence in Sicily of rural, urban, industrial, moderate-t…

medicine.medical_specialtyPathologyEndocrinology Diabetes and MetabolismPopulationReview Articleregistryvolcanoeslcsh:Diseases of the endocrine glands. Clinical endocrinologyEndocrinologypapillaryEpidemiologythyroid cancermedicinerisk factorseducationThyroid cancergeographyeducation.field_of_studylcsh:RC648-665geography.geographical_feature_categorybusiness.industryIncidence (epidemiology)ThyroidCancermedicine.diseasemedicine.anatomical_structureVolcanoincidenceEtiologyepidemiologybusinessDemographyFrontiers in Endocrinology
researchProduct

The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode ps…

2021

The work was supported by Guarantors of Brain post-doctoral clinical fellowship to DQ; Clinician Scientist Medical Research Council fellowship (project reference MR/M008436/1) to MDF; Heisenberg professorship from the German Research Founda- tion (grant no. 389624707) to UR; the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The EU-GEI Project is funded by the European Community’s Seventh Framework Programme under grant agreement No. HEALTH-F2-…

medicine.medical_specialtyPsychosisPopulationNeurosciences. Biological psychiatry. NeuropsychiatryPHENOTYPESILLNESSPsychotic DisorderPredictive markersArticleCellular and Molecular NeuroscienceDEFICIT SYNDROMERisk FactorsFirst episode psychosismedicineSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.HumansCannabiClinical geneticsGenetic riskVALIDITYeducationSettore MED/25 - PsichiatriaSCHEDULEBiological PsychiatryMETAANALYSISCannabisUTILITYeducation.field_of_studyRisk FactorESQUIZOFRENIAASSOCIATIONCannabis usemedicine.diseaseBIFACTOR MODELPsychiatry and Mental healthPsychotic DisordersINTERRATER RELIABILITYSchizophreniaLinear ModelsSchizophreniaLinear ModelMedical geneticsPolygenic risk scorePsychologyHumanRC321-571Clinical psychology
researchProduct

Dual-release hydrocortisone improves hepatic steatosis in patients with secondary adrenal insufficiency: A real-life study

2019

Background:Conventional glucocorticoid treatment has a significant impact on liver in patients with adrenal insufficiency. Dual-release hydrocortisone (DR-HC) provides physiological cortisol exposure, leading to an improvement in anthropometric and metabolic parameters. We aimed to evaluate the effects of 12-month DR-HC treatment on the hepatic steatosis index (HSI), a validated surrogate index of hepatic steatosis, in patients with secondary adrenal insufficiency (SAI).Methods:A total of 45 patients with hypopituitarism, 22 with hypogonadism, hypothyroidism, ACTH, and GH deficiencies, and 23 with hypogonadism, hypothyroidism, and ACTH deficiency, on replacement therapy for all the pituitar…

medicine.medical_specialtySecondary adrenal insufficiencyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismHypopituitarismHepatic steatosilcsh:Diseases of the endocrine glands. Clinical endocrinologyHypopituitarismSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdrenal insufficiencyIn patientHydrocortisoneOriginal Researchlcsh:RC648-665business.industryhepatic steatosismedicine.diseaseInsulin sensitivityEndocrinology030220 oncology & carcinogenesisDual-release hydrocortisoneSteatosisLife studybusinessGlucocorticoidmedicine.drugSecondary adrenal insufficiency
researchProduct